Literature DB >> 12396014

Mechanisms of C1-inhibitor deficiency.

Emanuela Pappalardo, Lorenza C Zingale, Adelaide Terlizzi, Andrea Zanichelli, Anna Folcioni, Marco Cicardi.   

Abstract

C1 inhibitor (C1-Inh) is a protease inhibitor of the serpin family. It interacts and forms complexes with several serine proteases although not all these interactions were proved to be relevant in vivo. Based on studies in deficient patients, C1-Inh appears pivotal in regulating the activation of complement classical pathway and of contact system. The best recognized consequence of defective C1-Inh function is predisposition to episodes of self-limited, increased vascular permeability (angioedema) that is restricted to three specific sites, which include the subcutaneous space, the gut and the upper airway. Candidate mediator of angioedema is bradykinin, a potent vasoactive peptide, released upon contact system activation. Mutations in C1-Inh structural gene are the most common cause of C1-Inh deficiency and lead to hereditary angioedema. Recurrent angioedema are also seen in the acquired defect of C1-Inh that is due to autoantibodies against this protein or to an associated disease causing accelerated catabolism of C1-Inh. Apart from the profound deficiency of C1-Inh characteristic of angioedema, it has been suggested that, in specific pathologic settings, C1-Inh levels in the low normal range could still represent a significant functional deficiency. Such conditions, as extensively investigated in sepsis, are of great relevance because they open the possibility of using C1-Inh as therapeutic agent in several different diseases.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12396014     DOI: 10.1078/0171-2985-00153

Source DB:  PubMed          Journal:  Immunobiology        ISSN: 0171-2985            Impact factor:   3.144


  17 in total

Review 1.  Therapeutic approaches in hereditary angioedema.

Authors:  Sabina Antonela Antoniu
Journal:  Clin Rev Allergy Immunol       Date:  2011-08       Impact factor: 8.667

Review 2.  Modern complement analysis.

Authors:  Michael Kirschfink; Tom E Mollnes
Journal:  Clin Diagn Lab Immunol       Date:  2003-11

3.  New insight into the effects of heparinoids on complement inhibition by C1-inhibitor.

Authors:  F Poppelaars; J Damman; E L de Vrij; J G M Burgerhof; J Saye; M R Daha; H G Leuvenink; M E Uknis; M A J Seelen
Journal:  Clin Exp Immunol       Date:  2016-04-13       Impact factor: 4.330

Review 4.  Acquired angioedema in juvenile systemic lupus erythematosus: case-based review.

Authors:  Zahide Ekici Tekin; Gülçin Otar Yener; Selçuk Yüksel
Journal:  Rheumatol Int       Date:  2018-06-27       Impact factor: 2.631

5.  The Rheumatoid Arthritis-Associated Citrullinome.

Authors:  Ronak Tilvawala; Son Hong Nguyen; Aaron J Maurais; Venkatesh V Nemmara; Mitesh Nagar; Ari J Salinger; Sunil Nagpal; Eranthie Weerapana; Paul R Thompson
Journal:  Cell Chem Biol       Date:  2018-04-05       Impact factor: 8.116

6.  Gene therapy for C1 esterase inhibitor deficiency in a Murine Model of Hereditary angioedema.

Authors:  Ting Qiu; Maria J Chiuchiolo; Adele S Whaley; Anthony R Russo; Dolan Sondhi; Stephen M Kaminsky; Ronald G Crystal; Odelya E Pagovich
Journal:  Allergy       Date:  2019-03-19       Impact factor: 13.146

Review 7.  Management of acute attacks of hereditary angioedema: potential role of icatibant.

Authors:  Hilary J Longhurst
Journal:  Vasc Health Risk Manag       Date:  2010-09-07

Review 8.  Life-threatening angioedema in a patient with systemic lupus.

Authors:  Chao-Hsien Ko; Jennifer Ng; Sunil Kumar; Miriam Hurst
Journal:  Clin Rheumatol       Date:  2006-03-18       Impact factor: 2.980

Review 9.  Clinical Immunology Review Series: An approach to the patient with angio-oedema.

Authors:  S Grigoriadou; H J Longhurst
Journal:  Clin Exp Immunol       Date:  2009-03       Impact factor: 4.330

Review 10.  Genetics of Hereditary Angioedema Revisited.

Authors:  Anastasios E Germenis; Matthaios Speletas
Journal:  Clin Rev Allergy Immunol       Date:  2016-10       Impact factor: 8.667

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.